Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026

About this update from Sutro Biopharma, Inc.

STRO-004 demonstrates robust and consistent antitumor activity across multiple TF-expressing solid tumor PDX models, with improved efficacy versus benchmark ADCs STRO-006 and STRO-227 show meaningful, dose-dependent antitumor activity across solid tumor models Presentation of TROP2-targeted immunostimulatory ADC program partnered with Astellas highlights the potential of Sutro’s platform for developing dual-payload ADCs SOUTH SAN FRANCISCO, Calif., April 19, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced promising preclinical data across its pipeline of next- generation ADCs in five posters and one oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026. Of note, results from a preclinical study of STRO-004, its DAR8 Topo1 ADC targeting Tissue Factor (TF), were reviewed today in an oral presentation titled “STRO-004, an exatecan-based next-generation tissue factor (TF)-targeted ADC, demonstrates superior efficacy across TF-expressing solid tumors in a comprehensive single-mouse PDX trial.” In the preclinical study, STRO-004 demonstrated robust and consistent antitumor activity across a broad range of TF-expressing solid tumor patient-derived xenograft (PDX) models, with improved efficacy compared to benchmark ADCs. At a single, clinically relevant dose of 5 mg/kg, STRO-004 achieved remarkable disease control and tumor reduction across multiple tumor types. STRO-004’s favorable tolerability, with a highest non-severely toxic dose (HNSTD) of 50 mg/kg, and pharmacokinetic profile are expected to enable increased drug exposure and payload delivery, supporting the Company’s belief that STRO-004 will demonstrate superior depth and durability of response in the clinic. Exploratory biomarker analyses provide preliminary insight into STRO-004's mechanism of action, suggesting potential for combination studies addressing specific indications in either early or late lines of treatment. “The STRO-004 preclinical data presented today underscore the potential of our next-generation ADCs to drive meaningful activity across multiple solid tumors,” said Jane Chung, Sutro’s Chief Executive Officer. “As STRO-004 advances in the clinic – with initial results from our Phase ...

View stock analysis, news, and events for Sutro Biopharma, Inc.